- Nano cap Biocept (NASDAQ:BIOC) is up 28% premarket on robust volume in reaction to the commercial launch of its Target Selector NGS Lung panel, a multi-gene liquid biopsy test for lung cancer.
Biocept up 28% premarket on launch of lung cancer test
Recommended For You
About BIOCQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BIOCQ | - | - |
Biocept, Inc. |